Navigation Links
ETEX Corporation Announces Additional FDA Clearance For EquivaBone(R), The First Hard Setting Osteoconductive and Osteoinductive Bone Graft Substitute.

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, announced today additional FDA 510(k) cleared indications for EquivaBone®. EquivaBone was the first FDA cleared hard-setting osteoinductive material and is the only osteoinductive bone graft substitute that provides a continuous nanocrystalline calcium phosphate scaffold.

(Logo: )

EquivaBone is now additionally indicated for use in posterolateral spine fusion, providing spine surgeons a product that combines the certified osteoinductivity of DBM with the optimal handling and hard setting characteristics of the clinically proven ETEX calcium phosphate osteoconductive scaffold.

In addition, the clearance allows EquivaBone to be mixed with autologous blood, adding greater procedural flexibility. The resultant viscous putty can then be molded and packed or injected into a defect.

Brian Ennis, President and CEO of ETEX Corporation, comments, "ETEX is pleased with the rapid expansion of clinical indications for our innovative biologic portfolio. Our product improvements and line extensions remain driven by direct surgeon feedback. This is reflected in the recent clearance of small size EquivaBone kits and the addition of blood and posterolateral spinal fusion indications to the labeling. We anticipate additional indications and platform extensions in the near term."

EquivaBone is a proprietary combination of osteoinductive Demineralized Bone Matrix (DBM) and ETEX's osteoconductive nanocrystalline calcium phosphate. ETEX is proud to offer the first combination product that is both moldable and injectable and sets hard once implanted. In addition, the osteoinductivity of the DBM is certified after sterilization, by lot, for the entirety of shelf life.

About ETEX Corporation

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit

SOURCE ETEX Corporation

SOURCE ETEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... -- Linden Care, LLC, a retail specialty pharmacy focused on ... from chronic pain, said today that it is disappointed ... enjoining Express Scripts from unilaterally terminating the Pharmacy Provider ... --> The company said that it ... --> --> In the ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) ... supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk ...
(Date:11/26/2015)... ... November 26, 2015 , ... The ... bioavailability and the need to integrate dose form selection in early phase drug ... the membership organization supporting and bringing together the UK’s emerging life sciences companies, ...
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
Breaking Medicine News(10 mins):